Preliminary, Real-world, Multicenter Experience With Omadacycline for <i>Mycobacterium abscessus</i> Infections
Taylor Morrisette, Sara Alosaimy, Julie V. Philley, Carly Wadle, Catessa Howard, Andrew Webb, Michael P. Veve, Melissa Barger, et al. (15 authors)
Open Forum Infectious Diseases · 2021-01
Abstract
Abstract Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
MeSH terms
- Medicine
- Interquartile range
- Mycobacterium abscessus
- Regimen
- Mycobacterium avium complex
- Internal medicine
- Adverse effect
- Nontuberculous mycobacteria
- Mycobacterium
- Surgery